CDC clears broader RSV, meningococcal shots for adults at risk
The CDC has approved the expanded use of RSV and meningococcal vaccines from Pfizer, Moderna, and GSK, even as its advisory panel considers major changes. Adults aged 50-59 at risk can now get RSV shots. GSK's new 5-in-1 meningococcal vaccine also received backing. Moderna saw extremely bullish sentiment on Stocktwits after the update.